sellWeak cluster of 5
Claudia Ibarra sold $1,232 of DMTK
Chief Operating Officer at DermTech, Inc.. 378 shares at an average of $3.26, traded Mar 13, 2023, filed Mar 15, 2023.
Warning score
35Value
$1,232
378 shares
Holdings after
214,705
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RoleCOO
- 0Trade size$1k at market
- 0Share of holdings soldSold 0.2% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-019064, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 13, 2023 | SOpen-market sale Common Stock | -378 | $3.26 | $1,232 | 214,705 | Mar 15, 2023 |
Related signals
Other insiders at DermTech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | DermTech, Inc. | Ramin Akhavan General Counsel | $5,765 3,768 shares | -3% | |
| 35Weak | DermTech, Inc. | Claudia Ibarra Chief Operating Officer | $10k 6,849 shares | -3% | |
| 37Weak | DermTech, Inc. | Kevin M Sun Chief Financial Officer | $8,266 5,426 shares | -2% | |
| 30Weak | DermTech, Inc. | Ramin Akhavan General Counsel | $8,745 4,531 shares | -3% | |
| 35Weak | DermTech, Inc. | Claudia Ibarra Chief Operating Officer | $15k 7,700 shares | -4% | |
| 37Weak | DermTech, Inc. | Kevin M Sun Chief Financial Officer | $19k 9,616 shares | -3% | |
| 35Weak | DermTech, Inc. | Claudia Ibarra Chief Operating Officer | $918 322 shares | -0% | |
| 37Weak | DermTech, Inc. | Kevin M Sun Chief Financial Officer | $1,245 437 shares | -0% | |
| 30Weak | DermTech, Inc. | Todd Michael Wood Chief Commercial Officer | $998 350 shares | -0% | |
| 30Weak | DermTech, Inc. | Ramin Akhavan General Counsel | $9,553 3,776 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.